This website is for Healthcare Professionals only.
TEPKINLY RESOURCES
See links to downloadable materials that may be useful references in your routine clinical practice.
Dosing and Administration
[INCLUDE SAFETY INFORMATION PER LOCAL REGULATIONS]
I would like to request a meeting with an AbbVie representative.
TEPKINLY is specifically engineered for high-specificity binding and minimal off-target effects.1,2
TEPKINLY as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
References: 1. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. Published online December 22, 2022. doi:10.1200/JCO.22.01725 2. Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625. doi:10.1016/j.ebiom.2019.102625 3. TEPKINLY Summary of Product Characteristics. AbbVie Inc.
ALL-EPCOR-230034